Navigation Links
New study finds no benefit to selecting dose of blood thinner based on patients' genetic makeup

DALLAS A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has determined that a gene-based method for selecting patients' doses of the popular heart medication warfarin is no better than standardized dosing methods. The study was presented today at the 2013 Scientific Sessions of the American Heart Association and published simultaneously in the New England Journal of Medicine.

"There has been much interest in the medical community about the utility of pharmacogenetics using information about a person's genetic makeup to choose the drugs and drug doses that are most likely to work well for that particular person to help better personalize treatments for patients and improve drug safety and efficacy," said lead study author Stephen Kimmel, MD, MSCE, professor of Medicine and Epidemiology at Penn Medicine. "Warfarin therapy has served as a model for the promise of a gene-based approach to patient care, but we needed a large, prospective clinical trial to determine if a patient's genetic information provides the added benefit above and beyond what can be obtained simply with clinical information."

Warfarin is a blood thinner used to prevent clots and is generally considered to be a very effective medication, but dosing must be properly adjusted for each patient, who are closely monitored for complications. Approximately 2 million Americans, primarily older patients, take warfarin to keep blood from excessive clotting, or coagulation. Currently, doctors face major challenges in determining the right dose of warfarin for each patient because individuals vary widely in how quickly their bodies' break down and respond to the drug. Taking too much warfarin could result in bleeding problems and taking too little warfarin will not stop clots from forming.

Previous research has shown that two genes, CYP2C9 and VKORC1, which vary among different individuals, can influence warfarin's effectiveness. In 2007 and 2010, the FDA worked with the makers of warfarin drug products to modify the product label to indicate that a patient's genetic makeup may affect how he or she responds to the drug and that genetic information might be useful in determining the optimal starting dose.

To find out whether these genes could help clinicians prescribe an optimal dose, the Clarification of Optimal Anticoagulation through Genetics (COAG) trial consisting of 18 clinical sites across the country and funded by the National Heart, Lung and Blood Institute (NHLBI) tested two approaches for determining the best initial dose of warfarin in patients who were expected to need therapy for at least one month or longer by clinical information alone or by clinical information plus specific genetic information. The four-year study included 1,015 patients randomly assigned to one of two groups during the first five days of initiating warfarin therapy.

For the patients in the clinical-based dosing group, the initial warfarin dose was determined using step-by-step procedures based only on information about clinical factors, such as age, sex, weight, ethnicity, and the use of other medications. In the gene-based dosing group, the initial dose was determined using this same clinical information as well as information about the patient's genetic makeup, including analyzing the participants' DNA for the CYP2C9 and VKORC1 genes. Patients and their providers were blinded to the dose of warfarin for the first month of therapy.

The researchers found that there was no difference among the two groups in mean percentage of time in therapeutic range (PTTR) for the medication (45.2 percent in the pharmacogenetic-dosing group versus 45.4 percent in the clinical-guided dosing group) at four-weeks. There was, however, a statistically significant difference by race. Among African Americans, the mean PTTR for the pharmacogenetic-guided dosing group was less than that for the clinical-guided dosing group 35.2 percent versus 43.5 percent, respectively. Pharmacogenetic-based dosing also led to more over-anticoagulation and a longer time to first therapeutic levels of the warfarin among African Americans.

The authors note that despite the positive results from other smaller studies analyzing the benefits of gene-based prescribing therapy, the results of this trial do not support the hypothesis that initiating warfarin therapy at a pharmacogenetic-predicted maintenance dose improves anticoagulation control over clinical methods. They point out that previous studies were primarily conducted at single clinical sites, were not blinded, and involved a limited number participants. They conclude that the COAG trial emphasizes the importance of performing large randomized trials for additional pharmacogenetics approaches, particularly for complex medicine regimens such as warfarin.


Contact: Jessica Mikulski
University of Pennsylvania School of Medicine

Related medicine news :

1. New study reports on the high cost of cardiac surgery healthcare associated infections
2. New Study May Impact Practice Guidelines for Mitral Valve Surgery for Severe Ischemic Mitral Regurgitation
3. Study may impact guidelines for mitral valve surgery for severe ischemic mitral regurgitation
4. Advanced CT imaging proves as accurate as invasive tests to assess heart blockages, study shows
5. Chicago man breathes again thanks to Northwestern Medicine study
6. Study finds youth prefer and benefit more from rapid point-of-care HIV testing
7. Study: Ureteral injury during robot-assisted prostate surgery
8. Study: Odds of rehospitalization of cognitively impaired varies by discharge destination
9. A CNIO study recreates the history of life through the genome
10. Dr. Joe Dentistry Promotes Dental Exams as New Study Links Heart Disease to Oral Health
11. Study questions hypothermia treatment for cardiac arrest
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... MOSI recently added ... Sea along with Back to the Jurassic to their collection of interactive exhibits within ... created dynamic worlds that will allow guests to get closer than ever to a ...
(Date:11/30/2015)... ... 2015 , ... The world of hair transplants and restoration is filled with ... and procedures have been in use for many years and are among the most ... M.D. has utilized many of these methods over the years, he also keeps an ...
(Date:11/30/2015)... ... November 30, 2015 , ... On Saturday, October 24th, 2015, at the Mill ... fundraising event, a 5K walk known as “Making Strides Against Breast Cancer”. Patients and ... is also located in Battle Creek, joined in for this campaign that sought to ...
(Date:11/30/2015)... CA (PRWEB) , ... November 30, 2015 , ... The ... matters of personal styling. So why is it a national news story when Donald ... to Parsa Mohebi, M.D., because appearances count more than anyone wants to admit when ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to an article published November ... slightly unusual choice to show her Instagram followers that the praise that they were ... pre-mature. Saying that she didn’t “want to mislead any mommy's who just had babies ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... the launch of Radiology Solutions, a fully integrated, ... Solutions comprises customized, data-driven practice management approaches that ... help radiology practices improve care delivery and reduce ... Radiological Society of North America Annual Meeting (RSNA) ...
(Date:11/30/2015)... , Nov. 30, 2015  IBA Molecular North ... and distribution of radiopharmaceuticals, announced that as of January ... Inc. (Zevacor Pharma). The decision to rebrand the company ... firm as well as its close relationship with Zevacor ... Illinois Health and Science (IHS). Peter ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, 2015 ... Public Research (the Institute) announced today that it ... a medical device start-up company with technology developed at ... based on publicly-funded research, and bridges early funding gaps ... -based universities and research institutions. ...
Breaking Medicine Technology: